Medical/Pharmaceuticals

So-Young to Report First Quarter 2026 Financial Results on May 22, 2026

BEIJING, May 14, 2026 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced that it will report its financial results for the first...

2026-05-14 17:00 3753

EBT Medical and NinaMED Announce US$13.75M Financing to Advance Licensed NiNA System® for Overactive Bladder

* US$13.75M financing completed to accelerate clinical pathway and global commercialisation * Establishment of NinaMED Pty Ltd, a new Australian medtech company * NinaMED Pty Ltd secures a license from EBT Medical for exclusive global rights to NiNA System®, a non‑invasive, at‑home OAB thera...

2026-05-14 13:03 3323

METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Ushers in a New Era of Biopharmaceuticals

HONG KONG, May 13, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a tech-bio company focused on AI-powered nanodelivery innovation, today successfully listed on the Hong Kong Stock Exchange (HKEX), becoming the world's first publicly listed AI-powered drug delivery company and the first AI-powered...

2026-05-14 10:09 4897

Elabscience® Launches Self-Developed PolyHRP-Streptavidin Conjugate for Low-Abundance Biomarker Detection in ELISA

HOUSTON, May 13, 2026 /PRNewswire/ -- Elabscience® Bionovation Inc. ("Elabscience®" or "the Company") today announced the launch of its self-developed PolyHRP-Streptavidin conjugate, a signal amplification reagent designed to improve enzyme-linked immunosorbent assay (ELISA) sensitivity for low-...

2026-05-14 00:00 3464

Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility

* The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialized solutions for payload-linkers. * This cutting-edge suite will significantly enhance the company's ability to support global payload-linke...

2026-05-13 22:45 3788

High-Trend International Group Announces Pricing of $15 Million Registered Direct Offering with Global Institutional Investors

NEW YORK, May 13, 2026 /PRNewswire/ -- High-Trend International Group (NASDAQ: HTCO) ("HTCO" or the "Company"), a global ocean transportation company, today announced that it has entered into securities purchase agreements with global institutional investors for the purchase and sale of 2,307,700...

2026-05-13 20:00 5150

New Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function

HONG KONG, May 12, 2026 /PRNewswire/ -- A major new clinical study, SUPER 2, has been published in Nature Communications, reporting that Efsubaglutide Alfa, a long-actingGLP-1 receptor agonist, significantly improved glycaemic control in adults with type 2 diabetes inadequately controlled on metf...

2026-05-13 11:47 3884

WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index

SHANGHAI, May 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included i...

2026-05-13 11:33 4534

Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions

SAN FRANCISCO and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2026-05-13 08:00 5142

Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China

CRANBURY, N.J. and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), and Dark Horse Consulting Group ("DHCG" or "the Group"), a leader in strategic and oper...

2026-05-12 23:00 5611

Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development

SHANGHAI, May 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a biotechnology company powered by generative artificial intelligence , today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd.  ("Ribo", 06938.HK), a ...

2026-05-12 20:30 4675

DNA 'barcodes' help NUS researchers pinpoint gold nanoparticles that can strike cancer at its power source

A new high-throughput platform screens dozens of nanoparticle designs in living systems to identify those that reach tumour mitochondria, enabling more precise and effective cancer therapies SINGAPORE, May 12, 2026 /PRNewswire/ -- Researchers at the National University of Singapore (NUS) have de...

2026-05-12 14:59 6478

GIP Moves from Supporting Role to Key Variable: BrightGene Bio-Medical's Phase III Results Signal Differentiation in Weight Loss Arena

SUZHOU, China, May 12, 2026 /PRNewswire/ -- As competition in the weight loss drug market progressively intensifies, the latest Phase III clinical data disclosed by BrightGene Bio-Medical (688166.SH) for BGM0504 has reignited market attention. Mean weight reduction of 19.3%, waist circumference ...

2026-05-12 14:08 2921

Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreements include 13 programs with the potential to address significant unmet patient needs and support long‑term growth SHANGHAI and PRINCETON, N.J.,...

2026-05-12 12:27 3521

Ranok Therapeutics Announces the Publication of Positive Phase 1a Clinical Results for KRAS G12D Inhibitor RNK08954 in Cancer Discovery

BOSTON and HANGZHOU, China, May 11, 2026 /PRNewswire/ -- Ranok Therapeutics, a clinical-stage biotechnology company developing innovative therapies, today announced the publication of preliminary clinical results from its Phase 1a study of RNK08954 in the peer-reviewed journal Cancer Discovery. R...

2026-05-11 21:00 5324

Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape

NANJING, China, May 11, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) successfully held its R&D Symposium in Shanghai. Under the theme "Leads Innovation, Future Forward", the event comprehensively presented the Company's strategic elevation from "mul...

2026-05-11 19:00 5160

ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D

NEWARK, Del., May 9, 2026 /PRNewswire/ -- ACROBiosystems has implemented a major upgrade to its global licensing framework for HEK293 functional cell lines, transitioning from a complex administrative process to a streamlined, purchase-based authorization model. This policy shift addresses the i...

2026-05-10 01:30 6712

World's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application

SHANGHAI, May 8, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Investigational New Drug (IND) application for 9MW5211, its independently developed novel antibody, has received clearance...

2026-05-09 08:00 6676

The 23rd World Congress on Breast Cancer and Breast Healthcare to Be Held in Tianjin

TIANJIN, China, May 8, 2026 /PRNewswire/ -- To further promote academic exchange and practical collaboration in the global field of breast health, and to advance the standardized prevention and treatment of breast cancer, the 23rd World Congress on Breast Cancer and Breast Healthcare will be held...

2026-05-08 17:06 3511

Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, May 8, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today annou...

2026-05-08 17:02 4665
1 ... 15161718192021 ... 262